KOREA PHARMA Past Earnings Performance
Past criteria checks 2/6
KOREA PHARMA's earnings have been declining at an average annual rate of -38.2%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 3.1% per year. KOREA PHARMA's return on equity is 4.2%, and it has net margins of 3.7%.
Key information
-38.2%
Earnings growth rate
-42.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 3.1% |
| Return on equity | 4.2% |
| Net Margin | 3.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is KOREA PHARMA (KOSDAQ:032300) A Risky Investment?
Nov 12
Optimistic Investors Push KOREA PHARMA Co., Ltd. (KOSDAQ:032300) Shares Up 29% But Growth Is Lacking
Oct 16KOREA PHARMA (KOSDAQ:032300) Seems To Use Debt Quite Sensibly
Mar 26What You Need To Know About KOREA PHARMA Co., Ltd.'s (KOSDAQ:032300) Investor Composition
Jan 08
Revenue & Expenses Breakdown
How KOREA PHARMA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 80,403 | 2,995 | 25,676 | 2,444 |
| 31 Mar 24 | 83,137 | 1,327 | 26,179 | 2,249 |
| 31 Dec 23 | 83,240 | 84 | 26,581 | 2,313 |
| 30 Sep 23 | 84,549 | -2,430 | 26,521 | 2,114 |
| 30 Jun 23 | 85,160 | -3,030 | 26,338 | 2,134 |
| 31 Mar 23 | 82,782 | -1,592 | 25,899 | 2,212 |
| 31 Dec 22 | 81,029 | -1,119 | 25,086 | 2,452 |
| 30 Sep 22 | 81,509 | 3,550 | 24,977 | 2,547 |
| 30 Jun 22 | 80,353 | 4,372 | 24,629 | 3,487 |
| 31 Mar 22 | 80,283 | 6,035 | 24,874 | 4,276 |
| 31 Dec 21 | 79,577 | 6,368 | 24,345 | 4,893 |
| 30 Sep 21 | 75,089 | 5,468 | 23,642 | 4,907 |
| 30 Jun 21 | 74,394 | 4,949 | 22,681 | 5,838 |
| 31 Mar 21 | 72,829 | 3,297 | 21,574 | 6,365 |
| 31 Dec 20 | 71,510 | 3,159 | 21,658 | 6,221 |
| 30 Sep 20 | 69,853 | 3,075 | 21,909 | 6,437 |
| 31 Mar 20 | 66,495 | 4,426 | 22,181 | 3,700 |
| 31 Dec 19 | 66,136 | 5,528 | 22,124 | 2,680 |
| 31 Dec 18 | 60,484 | 3,828 | 19,752 | 2,207 |
| 31 Dec 17 | 56,018 | 2,514 | 20,422 | 83 |
| 31 Dec 16 | 53,702 | -149 | 18,392 | 26 |
| 31 Dec 15 | 60,058 | 4,341 | 26,593 | 46 |
| 31 Dec 14 | 54,829 | 5,245 | 21,425 | 41 |
| 31 Dec 13 | 50,046 | 2,930 | 21,024 | 1 |
Quality Earnings: A032300 has high quality earnings.
Growing Profit Margin: A032300 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A032300's earnings have declined by 38.2% per year over the past 5 years.
Accelerating Growth: A032300 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A032300 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A032300's Return on Equity (4.2%) is considered low.